硼替佐米对老年多发性骨髓瘤病人IL-6、CRP和β2-MG水平的影响及疗效观察  

Effect of bortezomib on levels of IL-6,CRP and β2-MG in elderly patients with multiple myeloma

作　　者：童勇 孙志强 朱华民 凌宇 郝丹 周婴 包世杰 冯春[2] 杜飞[3] TONG Yong;SUN Zhi-qiang;ZHU Hua-min;LING Yu;HAO Dan;ZHOU Ying;BAO Shi-jie;FENG Chun;DU Fei(Department of Hematology,Shenzhen Hospital,Southern Medical University,Shenzhen 518000,China;Department of Hematolog;Department of Blood transfusion,China Three Gorges University People＇s Hospital,Yichang 443000,China)

机构地区：[1]南方医科大学深圳医院血液科,广东省深圳市518000 [2]三峡大学人民医院血液科,湖北省宜昌市443000 [3]三峡大学人民医院输血科,湖北省宜昌市443000

出　　处：《实用老年医学》2018年第10期966-969,共4页Practical Geriatrics

摘　　要：目的探讨硼替佐米对老年多发性骨髓瘤(MM)病人白细胞介素-6(IL-6)、C反应蛋白(CRP)和β2-微球蛋白(β2-MG)水平的影响及疗效观察。方法选取60例老年MM病人,随机分为观察组(n=30)和对照组(n=30),对照组采用常规化疗治疗,观察组在常规化疗的基础上联合硼替佐米治疗,比较2组治疗前后IL-6、CRP、β2-MG、M蛋白、血红蛋白水平和骨髓瘤细胞比例的变化,观察2组临床疗效及不良反应发生情况。结果治疗前2组IL-6、CRP、β2-MG、M蛋白、血红蛋白水平和骨髓瘤细胞比例差异无统计学意义(P>0. 05)。治疗后2组IL-6、CRP、β2-MG、M蛋白水平和骨髓瘤细胞比例低于治疗前,血红蛋白水平高于治疗前,且与对照组比较,差异均有统计学意义(P<0. 05)。观察组治疗总有效率为93. 33%,明显高于对照组(70. 00%)(P<0. 05)。2组间不良反应发生率比较差异无统计学意义(P>0. 05)。结论在常规化疗基础上联用硼替佐米治疗老年MM,能有效降低炎性应激反应,增强疗效,值得进一步研究。Objective To investigate the effect of bortezomib on levels of interleukin-6（ IL-6）,C reaction protein（ CRP） and β2-microglobulin（ β2-MG） in the elderly patients with multiple myeloma（ MM）. Methods A total of sixty elderly patients with MM were selected and randomly divided into observation group（ n = 30） and control group（ n = 30）. Patients in the control group were treated with conventional chemotherapy. Patients in the observation group were treated with bortezomib on the basis of conventional chemotherapy. The clinical efficacy and adverse reactions in the two groups were observed.And the levels of IL-6,CRP,β2-MG,M protein and myeloma cell ratio were compared between the two groups before and after treatment. Results There were no statistical difference in levels of IL-6,CRP,β2-MG,M protein,hemoglobin and myeloma cell ratio between the two groups before treatment（ P〈0. 05）. After treatment,the levels of IL-6,CRP,β2-MG,M protein and myeloma cells ratio were lower and the level of hemoglobin was higher in the two group than those before treatment,and the differences were also found between the two groups after treatment（ P〈0. 05）. After treatment,the total effective rate of the observation group was 93. 33%,which was significantly higher than that of the control group（ P〈0. 05）. There was no significant difference in adverse reactions between the two groups（ P〈0. 05）.Conclusions Combination of bortezomib based on the conventional chemotherapy in elderly patients with MM can reduce the inflammatory response and enhance efficacy.

关 键 词：硼替佐米 多发性骨髓瘤 白细胞介素-6 C反应蛋白 Β2-微球蛋白 

分 类 号：R733.3[医药卫生—肿瘤]